CN111494374B - 香草木宁碱在制备破骨细胞分化抑制剂中的应用 - Google Patents

香草木宁碱在制备破骨细胞分化抑制剂中的应用 Download PDF

Info

Publication number
CN111494374B
CN111494374B CN202010536342.0A CN202010536342A CN111494374B CN 111494374 B CN111494374 B CN 111494374B CN 202010536342 A CN202010536342 A CN 202010536342A CN 111494374 B CN111494374 B CN 111494374B
Authority
CN
China
Prior art keywords
vanilline
osteoclast differentiation
osteoporosis
osteoclast
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010536342.0A
Other languages
English (en)
Other versions
CN111494374A (zh
Inventor
刘志红
黄丹娥
徐峻
谢黎炜
顾琼
郑双佳
许国焕
韩木兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Microbiology of Guangdong Academy of Sciences
Original Assignee
Guangdong Detection Center of Microbiology of Guangdong Institute of Microbiology
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Detection Center of Microbiology of Guangdong Institute of Microbiology, Sun Yat Sen University filed Critical Guangdong Detection Center of Microbiology of Guangdong Institute of Microbiology
Priority to CN202010536342.0A priority Critical patent/CN111494374B/zh
Publication of CN111494374A publication Critical patent/CN111494374A/zh
Application granted granted Critical
Publication of CN111494374B publication Critical patent/CN111494374B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了香草木宁碱在制备破骨细胞分化抑制剂中的应用。香草木宁碱在制备破骨细胞分化抑制剂中的应用，所述的香草木宁碱，其结构式如式1所示。本发明通过试验发现，香草木宁碱对破骨细胞的分化具有直接而显著地抑制作用，因此可以作为破骨细胞分化抑制剂类药物，用于治疗破骨细胞分化引起的各类疾病，如骨质疏松症。
Figure DDA0002537190860000011

Description

香草木宁碱在制备破骨细胞分化抑制剂中的应用
技术领域
本发明属于生物医药领域，具体涉及香草木宁碱在制备破骨细胞分化抑制剂中的应用。
背景技术
骨质疏松是一种全身性骨代谢疾病，随着人类寿命的延长以及人口老龄化速度的加快，骨质疏松症发病率逐年升高，已成为影响人们生活质量的重要慢性病之一，成为全球公共健康问题。据2014年美国骨矿盐研究学会(ASBMR)年会上统计，骨质疏松性骨折是21世纪重要的慢性病之一，全球1/2的老年女性和1/3的老年男性将会发生骨质疏松性骨折。因此，开发有效的抗骨质疏松药物对于提高人类特别是老年人生活质量，减轻社会经济压力具有重要意义。
骨质疏松症是一种以骨量减少、骨组织微结构破坏、骨脆性增加和易于骨折为特征的代谢性骨病。目前抗骨质疏松药物治疗的作用机制主要分为两大类：抗骨吸收和促进骨形成。抗骨吸收涉及的靶点或通路主要有OPG/RANKL/RANK信号通路、组织蛋白酶K、C-src激酶。促进骨形成的相关靶点或通路有Wnt/β-catenin信号通路、骨形成蛋白、Activin信号通路以及甲状旁腺激素PTH。目前临床上抗骨吸收药物主要有双膦酸盐类(阿仑膦酸钠、伊班膦酸钠等)，雌激素受体调节剂(雷洛昔芬)，RANKL抑制剂(地诺单抗)，组织蛋白酶K抑制剂(奥当卡替)，src激酶抑制剂(Saracatinib)。促骨形成的药物主要有甲状旁腺激素类似物(特立帕肽PTH1-34)，Wnt信号通路调控剂(AMG785、BHQ880)等。这些药物虽然能在一定程度上提高骨质疏松患者的骨密度，但是不能显著降低非典型性骨折的风险，同时存在各种副作用，如双膦酸盐类药物会引起下颌骨坏死，雷洛昔芬会引起静脉栓塞。因此，我们亟需研究更有效、副作用更小的抗骨质疏松症治疗药物。
OPG/RANKL/RANK信号系统被确认是骨代谢中一个重要的信号通路，RANKL(receptor activator of NFκB ligand)与破骨细胞前体细胞或破骨细胞表面上的RANK结合，促进破骨细胞的分化和激活，并抑制其凋亡；骨保护素(osteoprotegerin，OPG)阻止RANKL与RANK的结合，起负调节作用。RANKL和OPG比率的动态平衡在骨吸收中起重要的控制作用。OPG-RANKL-RANK信号系统的研究成果是骨分子生物上的一个里程碑，不仅阐明了OPG-RANKL-RANK信号系统与破骨细胞的发育、成熟之间的存在的多种信号偶联，以及破骨细胞骨吸收与成功细胞成骨作用的偶联失衡，而且为骨质疏松症的发生机制奠定了一定的基础，为骨质疏松症的靶向治疗开辟了新的思路。目前针对OPG-RANKL-RANK系统，美国安进公司已开发出单抗药物地诺单抗，用于实体瘤骨转移患者中骨骼相关事件的预防，现在也在研究用于治疗骨质疏松症。随着OPG-RANKL-RANK晶体结构的解析，靶向OPG-RANKL-RANK抗骨质疏松的小分子多肽类药物成为研究热点。因此，靶向OPG-RANKL-RANK已被广泛证实是抗骨质疏松治疗的重要策略。
发明内容：
本发明的目的是提供香草木宁碱或其药用盐在制备破骨细胞分化抑制剂中的应用。
破骨细胞分化活性测试显示化合物香草木宁碱可以剂量依赖抑制破骨细胞的成熟分化，IC50值为3.16μM。细胞毒性测试CC50为83.68μM。说明香草木宁碱具有很好的抑制活性，具有潜在开发抗骨质疏松药物的价值。
因此，可以将化合物香草木宁碱，或其药用盐用于制备破骨细胞分化抑制剂：
所述的香草木宁碱，其结构式如式1所示：
Figure BDA0002537190840000031
所述的破骨细胞分化抑制剂为抗骨质疏松性药物。
所述的破骨细胞分化抑制剂为口服剂型或外用剂型。
所述的破骨细胞分化抑制剂包括活性成分化合物香草木宁碱和药学上可接受的药用辅料。
本发明通过试验发现，化合物香草木宁碱对破骨细胞的分化具有直接而显著地抑制作用，因此可以作为破骨细胞分化抑制剂类药物，用于治疗破骨细胞分化引起的各类疾病，如骨质疏松症。
附图说明：
图1是香草木宁碱(Kokusaginine)剂量依赖抑制破骨细胞的成熟分化；
图2是香草木宁碱(Kokusaginine)抑制曲线及IC50值；
图3是香草木宁碱(Kokusaginine)细胞毒性测试。
具体实施方式：
实施例1：破骨细胞分化抑制活性测试
Figure BDA0002537190840000041
1、实验方法
细胞培养：取8周龄大小的C57BL/6小鼠股骨髓细胞，用含有10ng/mL M-CSF的MEM-α完全培养基(含10％胎牛血清(FBS),100U/mL青霉素和100μg/mL链霉素),在二氧化碳培养箱中于37℃条件下培养24h，弃掉培养液，用磷酸盐缓冲液(PBS)缓慢地冲洗细胞1～2次，去除悬浮细胞，然后用4mL MEM-α完全培养基将贴壁细胞轻轻吹下，于1000RPM/min离心10min，获得小鼠骨髓巨噬细胞(BMMs)。
诱导破骨细胞形成：用含10ng/mLM-CSF细胞因子的MEM-α完全培养基将BMMs细胞稀释成密度为1×105个细胞/mL的细胞悬液，并接种于96孔板中，每孔100μL。培养24h贴壁后，弃培养液，用含100ng/mL RANKL和10ng/mL M-CSF细胞因子的MEM-α完全培养基与BMMs细胞共培养4d诱导破骨细胞的形成。每2天换一次培养液。诱导培养结束后在倒置显微镜下观察破骨细胞形成情况并拍片保存。
TRAP染色及破骨细胞数量的测定：用含10ng/mL M-CSF细胞因子的MEM-α完全培养基将BMMs细胞稀释成密度为1×105个细胞/mL的细胞悬液，并接种于96孔板中，每孔100μL。培养24h贴壁后，弃培养液，用含100ng/mL RANKL，10ng/mL M-CSF和含不同终浓度化合物的MEM-α完全培养基与BMMs细胞共培养4d诱导破骨细胞的形成。每2天换一次培养液，每个处理3个重复。在相同条件下，只含有与药物溶液等体积的DMSO培养液的细胞作为诱导对照组。处理结束后，弃培养液，PBS清洗细胞，4％多聚甲醛细胞固定液将细胞固定10min。然后用抗酒石酸酸性磷酸酶(TRAP)染色液对BMMs细胞分化形成的破骨细胞进行染色。倒置相差显微镜下观察，TRAP染色阳性多核细胞(>3个核)计为破骨细胞。培养板中的各孔细胞随机选10个不同视野拍片保存,并用Image-Pro Plus 5.0软件计数TRAP染色阳性细胞数取平均值，计算相应药物浓度下的破骨细胞抑制率。
Figure BDA0002537190840000051
将药物浓度及其相对应的破骨细胞抑制率数值输入GraphPad Prism 8软件中，以药物浓度的Log值为横坐标，抑制率纵坐标，绘制IC50抑制曲线，选取软件自带的非线性拟合曲线法计算IC50值。
细胞毒性测试方法：取BMMs细胞，用含10ng/mLM-CSF细胞因子的MEM-α完全培养基将细胞密度稀释成1×105个细胞/mL的细胞悬液，并接种于96孔板中，每孔100μL。培养24h后，加入含不同终浓度化合物进行干预，空白对照组用同等体积的DMSO溶液代替，每个处理3个重复。继续培养24h后，弃去培养基，采用MTT法测定活细胞数，以570nm处波长测得的OD值进行评价，计算相应药物浓度下细胞生长抑制率。
Figure BDA0002537190840000052
将药物浓度及其相对应的细胞生长抑制率数值输入GraphPad Prism 8软件中，以药物浓度的Log值为横坐标，抑制率纵坐标，绘制CC50抑制曲线，选取软件自带的非线性拟合曲线法计算CC50值。
2、实验结果
结果如图1-3所示，从图1-3可以看出，破骨细胞分化活性测试显示香草木宁碱都可以剂量依赖抑制破骨细胞的成熟分化(图1)，IC50值为3.16μM(图2)。细胞毒性测试CC50为83.68μM。说明香草木宁碱具有很好的抑制活性，具有潜在开发抗骨质疏松药物的价值。
以上仅是本发明的优选实施方式，应当指出的是，上述优选实施方式不应视为对本发明的限制，本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说，在不脱离本发明的精神和范围内，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (3)

1.香草木宁碱或其药用盐在制备抗骨质疏松性药物中的应用，
所述的香草木宁碱其结构式如式1所示：
Figure 174450DEST_PATH_IMAGE002
式1。
2.根据权利要求1所述的应用，其特征在于，所述的抗骨质疏松性药物为口服剂型或外用剂型。
3.根据权利要求1或2所述的应用，其特征在于，所述的抗骨质疏松性药物包括活性成分化合物香草木宁碱或其药用盐，和药学上可接受的药用辅料。
CN202010536342.0A 2020-06-12 2020-06-12 香草木宁碱在制备破骨细胞分化抑制剂中的应用 Active CN111494374B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010536342.0A CN111494374B (zh) 2020-06-12 2020-06-12 香草木宁碱在制备破骨细胞分化抑制剂中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010536342.0A CN111494374B (zh) 2020-06-12 2020-06-12 香草木宁碱在制备破骨细胞分化抑制剂中的应用

Publications (2)

Publication Number Publication Date
CN111494374A CN111494374A (zh) 2020-08-07
CN111494374B true CN111494374B (zh) 2021-08-03

Family

ID=71878831

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010536342.0A Active CN111494374B (zh) 2020-06-12 2020-06-12 香草木宁碱在制备破骨细胞分化抑制剂中的应用

Country Status (1)

Country Link
CN (1) CN111494374B (zh)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825091B1 (fr) * 2001-05-23 2003-07-04 Servier Lab Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20090269772A1 (en) * 2008-04-29 2009-10-29 Andrea Califano Systems and methods for identifying combinations of compounds of therapeutic interest
CN104116684B (zh) * 2014-08-14 2016-05-25 郭宏刚 一种纯天然沐浴粉
CN104248670B (zh) * 2014-09-03 2015-08-19 广州诺金制药有限公司 一种治疗高血压的中药复方制剂及其制备方法

Also Published As

Publication number Publication date
CN111494374A (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
Wei et al. Alpinetin ameliorates bone loss in LPS-induced inflammation osteolysis via ROS mediated P38/PI3K signaling pathway
Song et al. Nuciferine prevents bone loss by disrupting multinucleated osteoclast formation and promoting type H vessel formation
Yan et al. Sirtuin 1 inhibits TNF-α-mediated osteoclastogenesis of bone marrow-derived macrophages through both ROS generation and TRPV1 activation
Zhao et al. Effects of interleukin‐7/interleukin‐7 receptor on RANKL‐mediated osteoclast differentiation and ovariectomy‐induced bone loss by regulating c‐Fos/c‐Jun pathway
Zhang et al. Flufenamic acid inhibits osteoclast formation and bone resorption and act against estrogen-dependent bone loss in mice
Yang et al. Scutellarin ameliorates osteoarthritis by protecting chondrocytes and subchondral bone microstructure by inactivating NF-κB/MAPK signal transduction
Zeng et al. Alpinetin alleviates osteoporosis by promoting osteogenic differentiation in BMSCs by triggering autophagy via PKA/mTOR/ULK1 signaling
Kim et al. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL
Sidor et al. 1-Methylnicotinamide (1-MNA) inhibits the activation of the NLRP3 inflammasome in human macrophages
Qiu et al. Neratinib exerts dual effects on cartilage degradation and osteoclast production in Osteoarthritis by inhibiting the activation of the MAPK/NF-κB signaling pathways
CN111494374B (zh) 香草木宁碱在制备破骨细胞分化抑制剂中的应用
Li et al. Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response
CN111686116B (zh) 孕甾烷衍生物在制备破骨细胞分化抑制剂中的应用
Wang et al. Phenobarbital inhibits osteoclast differentiation and function through NF-κB and MAPKs signaling pathway
Fei et al. Magnolol prevents ovariectomy‑induced bone loss by suppressing osteoclastogenesis via inhibition of the nuclear factor‑κB and mitogen‑activated protein kinase pathways
CN111658649B (zh) 生物碱在制备破骨细胞分化抑制剂中的应用
CN109730999B (zh) 噻唑苯甲酰胺衍生在制备抗骨质疏松、抗骨关节炎药物中的应用
KR20120037896A (ko) 데커신 또는 이의 유도체 화합물을 함유하는 퇴행성 신경질환의 예방 또는 치료용 조성물
Cao et al. Anemoside B4 attenuates RANKL-induced osteoclastogenesis by upregulating Nrf2 and dampens ovariectomy-induced bone loss
CN113616631B (zh) Dusp6抑制剂bci在制备骨质疏松药物中的应用
Ma et al. Tanshinone I attenuates estrogen-deficiency bone loss via inhibiting RANKL-induced MAPK and NF-κB signaling pathways
CN114191450B (zh) 普鲁士蓝及其类似物在制备预防、延缓或治疗骨质疏松症药物中的应用
Xiao et al. D (-)-salicin inhibits RANKL-induced osteoclast differentiation and function in vitro
CN109939109B (zh) N-噻唑-乙酰胺衍生物作为破骨细胞分化抑制剂在制备抗骨质疏松药物中的应用
KR20210149498A (ko) 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Xie Liwei

Inventor after: Liu Zhihong

Inventor after: Huang Dane

Inventor after: Xu Jun

Inventor after: Gu Qiong

Inventor after: Zheng Shuangjia

Inventor after: Xu Guohuan

Inventor after: Han Mulan

Inventor before: Liu Zhihong

Inventor before: Huang Dane

Inventor before: Xu Jun

Inventor before: Xie Liwei

Inventor before: Gu Qiong

Inventor before: Zheng Shuangjia

Inventor before: Xu Guohuan

Inventor before: Han Mulan

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220719

Address after: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province

Patentee after: Institute of Microbiology, Guangdong Academy of Sciences

Address before: 510070 No.56 courtyard, No.100 Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province

Patentee before: GUANGDONG INSTITUTE OF MICROBIOLOGY (GUANGDONG DETECTION CENTER OF MICROBIOLOGY)

Patentee before: Sun Yat-sen University